Some people with heart failure need to take multiple medicines each day in order to keep their symptoms under control. Heart failure not only leads to issues in the heart but other organs in the body ...
Treatment with dapagliflozin reduced the risk of death or worsening heart failure by 28% compared with standard of care. Dapagliflozin reduced the risk of death or worsening heart failure (HF) in ...
Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...
Dapagliflozin safe and effective in elderly patients with heart failure undergoing valve replacement
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
In a trial involving patients with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of worsening heart failure or cardiovascular death.
In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients
In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects ...
Patients with heart failure who took dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, after undergoing transcatheter aortic valve replacement (TAVR) were significantly less likely ...
Hosted on MSN
AstraZeneca’s Real-World Study on Dapagliflozin: Implications for Heart Failure Treatment
AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback